MISSISSAUGA, Canada, January 18 /PRNewswire/ -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that The Lancet, a world-leading medical journal, will publish an article entitled 'Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial' in its January 19th issue (Lancet 2008; 371: 228-36). The article describes the results from Vasogen's 2,400-patient ACCLAIM trial of its Celacade(TM) system in patients with chronic heart failure. Celacade is designed to target the destructive chronic inflammation underlying the development and progression of chronic heart failure.

CAMBRIDGE, England and LILLE, France, January 18 /PRNewswire/ --

- Irish and UK Blood Services Continue Pre-Adoption Clinical Evaluation of Filter

- Recent Case of vCJD Now Means That All the Population is Susceptible to the Disease

- Increased Concerns Over "Second Wave" of vCJD in Individuals With Much Longer Incubation Times

- P-Capt(R) Prion Reduction Filter Still the Only Proven Method of Protecting Against Potential Transmission of the Disease in Blood

- ProMetic and MacoPharma Gearing up for Implementation in Watershed Year for the Product

EVRY, France, January 18 /PRNewswire/ --

- Not for Distribution in the United States, Canada or Japan

Novagali Pharma, an emerging ophthalmic pharmaceutical company announced today that the Company's Investigational New Drug Application (IND) to conduct a Phase I clinical trial of its Nova63035, an ophthalmic injectable emulsion based on EYEJECT(R) technology containing a corticosteroid prodrug for the treatment of Diabetic Macular Edema (DME), has been granted by the U.S. Food and Drug Administration (FDA).

LEUVEN, Belgium and LUND, Sweden, January 18 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) announce today that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial of the novel anti-cancer agent TB-403. TB-403 is a monoclonal antibody that targets the angiogenic factor PlGF (placental growth factor). TB-403 has demonstrated strong inhibition of PlGF-associated angiogenesis and tumour growth in animal models, without affecting healthy tissues. This product candidate is being developed within the framework of the alliance between ThromboGenics and BioInvent.

SINGAPORE, January 18 /PRNewswire/ --

International Group, Ltd. (Bloomberg: BIG SP, Company or Biosensors), today announced that the Company has received Conformite Europeenne (CE) Mark approval for its BioMatrix(R) drug-eluting stent system, enabling commercialization of this product in the European Union and the countries in Asia and Latin America that recognize the CE Mark. The BioMatrix drug-eluting stent system, developed internally by the Company, consists of a unique drug-eluting stent that incorporates a biodegradable polymer and the Company's proprietary drug, Biolimus A9(R), which inhibits restenosis, or re-narrowing of the arteries, following stent implantation.

NEW YORK and AMSTERDAM, Netherlands, January 17 /PRNewswire/ --

Playlogic Entertainment, Inc. (OTC Bulletin Board: PLGC.OB) -- an independent worldwide publisher of entertainment software -- has appointed Pierre Thiercelin (33) as Chief Sales and Marketing Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071119/PLAYLOGICLOGO )

Pierre Thiercelin (France) joined Playlogic Entertainment in March 2007 as International Sales Director and actively contributed to the further development of the company's distribution network. In his new capacity, he will be responsible for Playlogic's worldwide sales, marketing and licensing activities.